Csl had a 5% fall in profit driven by lower plasma donations, which constrained sales of its core immunoglobulin products.

The global biotech said donation volumes improved materially in the second half, and the $143 billion business expects this pick up in volumes to underpin future immunoglobulin and albumin therapy sales growth.

Csl chief executive Paul Perreault said the result demonstrated the ?resilient performance? of the business against ongoing challenges caused by COVID-19.

Shares in Csl slipped 3.99% following the announcement.